Macroaxis Story

Macroaxis News
  
By Vlad Skutelnik

July 9, 2019

Today article will analyze 8 Compulsion isntruments to have in your portfolio in August 2019. I will specifically cover the following equities: Anheuser Busch InBev SANV, Merck Co, AstraZeneca PLC, Sanofi, Abbott Laboratories, Novartis AG, The Walt Disney Company, and Yamana Gold
The Top 8 Compulsion stocks to own in August 2019

This list of potential positions covers Addiction driven consumer products and services. Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.


Anheuser Busch Inbev SA Sponsor (BUD)

The company has Net Profit Margin of 13.81 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 41.64 % which entails that for every 100 dollars of revenue it generated 0.42 of operating income. The entity currently falls under 'Mega-Cap' category with total capitalization of 187.7B. Anheuser Busch Inbev shows prevailing Real Value of $115.64 per share. The current price of the firm is $95.29. At this time the firm appears to be undervalued. This module approximates value of Anheuser Busch Inbev from analyzing the firm fundamentals such as Return On Equity of 11.38% and Profit Margin of 13.81% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend. Anheuser Busch Inbev shows prevailing Real Value of $115.64 per share. The current price of the firm is $95.29. At this time the firm appears to be undervalued. This module approximates value of Anheuser Busch Inbev from analyzing the firm fundamentals such as Profit Margin of 13.81% and Return On Equity of 11.38% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.

Merck Company (MRK)

The company has Net Profit Margin of 21.1 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 38.73 % which entails that for every 100 dollars of revenue it generated 0.39 of operating income. The entity currently falls under 'Mega-Cap' category with total capitalization of 213.53B.
Total Debt
Merck secures last-minute Real Value of $86.2047 per share. The latest price of the firm is $85.06. At this time the firm appears to be fairly valued. This module forecasts value of Merck from analyzing the firm fundamentals such as Current Valuation of 240.98B, Return On Equity of 30.55% and Profit Margin of 21.10% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend to purchase undervalued stocks and to get rid of overvalued stocks since at some point entities prices and their ongoing real values will merge together.

Astrazeneca PLC (AZN)

The company has Net Profit Margin of 9.48 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 22.62 % which entails that for every 100 dollars of revenue it generated 0.23 of operating income. The entity currently falls under 'Mega-Cap' category with total capitalization of 114.79B. Astrazeneca PLC shows prevailing Real Value of $48.1619 per share. The current price of the firm is $44.34. At this time the firm appears to be undervalued. This module approximates value of Astrazeneca PLC from analyzing the firm fundamentals such as Current Valuation of 133.31B, Return On Equity of 14.21% and Profit Margin of 9.48% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend. Astrazeneca PLC competes with Hutchison China, Merck, Eli Lilly, Novartis, Johnson Johnson, GlaxoSmithKline PLC, Pfizer, and GW Pharmaceuticals. AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca PLC operates under Drug Manufacturers - Major classification in USA and is traded on BATS Exchange. It employs 64400 people.

Sanofi (SNY)

The company has Return on Asset of 3.6 % which means that on every $100 spent on asset it made $3.6 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 6.47 % implying that it generated $6.47 on every 100 dollars invested. This firm currently falls under 'Mega-Cap' category with total capitalization of 105B. Sanofi has current Real Value of $45.3 per share. The regular price of the company is $42.02. At this time the company appears to be undervalued. This module measures value of Sanofi from inspecting the company fundamentals such as Return On Equity of 6.47%, Current Valuation of 105.42B and Shares Owned by Insiders of 0.01% as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend to buy undervalued stocks and to dispose of overvalued stocks since at some point securities prices and their ongoing real values will draw towards each other.

Abbott Laboratories (ABT)

The company has Net Profit Margin of 9.36 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 24.33 % which entails that for every 100 dollars of revenue it generated 0.24 of operating income. The entity currently falls under 'Mega-Cap' category with total capitalization of 153.57B. Abbott Laboratories shows prevailing Real Value of $85.1257 per share. The current price of the firm is $84.78. At this time the firm appears to be fairly valued. This module approximates value of Abbott Laboratories from analyzing the firm fundamentals such as Profit Margin of 9.36% and Return On Equity of 9.21% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend. Abbott Laboratories shows prevailing Real Value of $85.1257 per share. The current price of the firm is $84.78. At this time the firm appears to be fairly valued. This module approximates value of Abbott Laboratories from analyzing the firm fundamentals such as Profit Margin of 9.36% and Return On Equity of 9.21% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.

Novartis AG (NVS)

The company has Net Profit Margin of 21.15 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 31.39 % which entails that for every 100 dollars of revenue it generated 0.31 of operating income. The entity currently falls under 'Mega-Cap' category with total capitalization of 208.05B.
Total Debt
Novartis AG secures last-minute Real Value of $94.1725 per share. The latest price of the firm is $89.47. At this time the firm appears to be undervalued. This module forecasts value of Novartis AG from analyzing the firm fundamentals such as Profit Margin of 21.15%, Current Valuation of 228.24B and Return On Equity of 10.74% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend to purchase undervalued stocks and to get rid of overvalued stocks since at some point entities prices and their ongoing real values will merge together.

Walt Disney Company (DIS)

The company has Net Profit Margin of 19.02 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 25.54 % which entails that for every 100 dollars of revenue it generated 0.26 of operating income. The entity currently falls under 'Mega-Cap' category with total capitalization of 244.52B. Walt Disney shows prevailing Real Value of $143.05 per share. The current price of the firm is $135.2. At this time the firm appears to be undervalued. This module computes value of Walt Disney from reviewing the firm fundamentals such as Current Valuation of 315.81B, Operating Margin of 25.54% and Return On Equity of 15.87% as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we advise to go long with undervalued instruments and to sell out overvalued instruments since at some point assets prices and their ongoing real values will submerge.

Yamana Gold (AUY)

The company has price-to-book (P/B) ratio of 0.78. Some equities with similar Price to Book (P/B) outperform the market in the long run. The entity has Price/Earnings To Growth (PEG) ratio of 0.62. The entity recorded loss per share of 0.14. The firm last dividend was issued on 2019-09-27. The entity had 1:27 split on 2003-08-21. The company currently falls under 'Mid-Cap' category with total capitalization of 3.15B.
Total Debt
Yamana Gold competes with AngloGold Ashanti, Hecla Mining, Kirkland Lake, Novagold Resources, Osisko Gold, GOLD RESERVE, Almaden Minerals, Agnico Eagle, and Alamos Gold. Yamana Gold Inc. engages in operating mines, development stage projects, and exploration and mineral properties primarily in Canada, Brazil, Chile, and Argentina. Yamana Gold Inc. was founded in 1980 and is based in Toronto, Canada. Yamana Gold operates under Gold classification in USA and is traded on BATS Exchange. It employs 5165 people.

Current 8 Compulsion Recommendations

Competition Technical Indicators

Mean
Deviation
Jensen
Alpha
Sortino
Ratio
Treynor
Ratio
Semi
Deviation
Information
Ratio
Expected
Shortfall
Potential
Upside
Value
At Risk
Maximum
Drawdown
 2.51  0.71  0.25 (1.44)  2.42  0.23 (2.97)  6.05 (2.70)  15.89 
 3.28 (0.27)  0.00 (2.98)  0.00 (0.05)  0.00  6.35 (8.19)  27.86 
 1.82  0.29  0.13 (1.37)  2.20  0.12 (2.40)  4.33 (2.66)  13.93 
 2.22  0.86  0.33 (3.44)  1.89  0.33 (2.43)  5.06 (3.68)  11.93 
 1.78  0.27  0.11 (0.41)  2.36  0.12 (1.92)  3.16 (3.91)  16.92 
 3.72 (0.53)  0.00  0.65  0.00 (0.06)  0.00  4.12 (5.56)  41.97 
 3.91  0.75  0.25 (0.44)  3.08  0.16 (5.54)  11.09 (4.75)  22.66 
 1.25  0.48  0.43 (2.86)  0.82  0.32 (1.72)  3.92 (1.91)  7.52 
 2.22  0.58  0.29 (1.11)  1.60  0.21 (2.88)  6.94 (3.47)  13.00 
 2.82  1.18  0.38 (1.73)  2.55  0.33 (3.79)  8.33 (4.08)  20.26 

About Contributor

Vlad Skutelnik
   Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered as solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Macroaxis. Please refer to our Terms of Use for any information regarding our disclosure principles.

Did you try this?

Run Portfolio File Import Now

   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Module
See also Stocks Correlation. Please also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of macroaxis ideas.
Search macroaxis.com